The conversation discusses managing estradiol problems during finasteride treatment. Suggestions include stopping finasteride every 3 months for 2-3 weeks or reducing the dosage.
A 28-year-old male reported significant hair regrowth using 5mg minoxidil and 0.5mg dutasteride over five months, with occasional ketoconazole use. Users discussed side effects like stuffy nose and low libido, and shared experiences with different hair loss treatments.
A 33-year-old man shares his positive hair regrowth results using 1mg finasteride daily, 5% topical minoxidil twice daily, and a 0.5mm dermaroller weekly. He feels more confident and encourages others to try the routine despite potential side effects.
A 54-year-old is considering taking oral minoxidil daily and dutasteride every second day due to side effects like low sex drive and erectile issues. Others suggest taking dutasteride less frequently, with some using testosterone supplements and Cialis to manage side effects.
A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.
User shared results of using minoxidil and dermaneedling for hair loss over 2.5 months, noting improvements, especially around the left temple. No finasteride or other anti-androgens were used.
The user is concerned about high estradiol and normal DHT levels after 6 months on finasteride and 4 months on weekly dutasteride, noticing hair thinning. They consider increasing dutasteride frequency and adding RU58841 to their regimen.
The conversation discusses reliable brands for RU58841, with recommendations for RUdirect and Receptorchem. Users also mention Anageninc as a known option for RU58841 in Europe and the UK.
The conversation discusses experimenting with microneedling for hair loss, with OP considering using a 3mm derma-stamp. Other users advise against going beyond 1.5mm to avoid damage.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
The conversation discusses using dermastamping for hair loss, with specific needle lengths of 1.25mm on the scalp and 1mm around the temples and crown. The user experiences tingling, slight bleeding, and redness, and seeks advice on frequency and effective schedules.
A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.
A user's experience with the Big 3 (minoxidil, finasteride and RU58841) hair loss treatment along with dermarolling. The dermaroller pin was 1.5mm used once per week and drew some blood but not a lot.
A user shared progress pictures showing successful hair retention using a low-dose topical finasteride (0.008%) combined with minoxidil. Users discussed the effectiveness of the treatment, minimal effective dosing, and avoiding systemic side effects.
Finasteride and dutasteride may cause erectile dysfunction due to reduced DHT, affecting nitric oxide and sexual function. Some suggest using aromatase inhibitors to address side effects, while others believe individual sensitivity to DHT reduction varies.
A 37-year-old is using 1mg oral finasteride, 5mg oral minoxidil, exosome treatments, TED, NOUVADerm, weekly microneedling, and PDO threads for hair loss. Users suggest waiting a few more months to see significant progress.
The user has been using finasteride for 4-5 years and recently started minoxidil to address hair loss, particularly in the crown area. They are considering adding PRP or exosome therapy but are concerned about interactions and effectiveness compared to proven treatments like finasteride, dutasteride, and minoxidil.